Moneycontrol PRO
HomeNewsBusinessMarketsEntero Healthcare to Acquire 60% Stake in Ace Cardiopathy

Entero Healthcare to Acquire 60% Stake in Ace Cardiopathy

Entero Healthcare to Acquire 60% Stake in Ace Cardiopathy

September 29, 2025 / 13:33 IST
Disclaimer This is an AI-assisted live blog with updates sourced from multiple news outlets and agencies Disclaimer
Image caption test
     
     
    26 Aug, 2025 12:21
    Volume
    Todays L/H
    More

    Entero Healthcare Solutions Limited announced that its board has approved the execution of a Share Purchase Agreement (SPA) to acquire a 60% stake in Ace Cardiopathy Solutions Private Limited, subject to satisfactory completion of due diligence and execution of the definitive agreements.

    The cost of acquisition shall range between ₹59.30 Crore to ₹77.10 Crore for acquiring 60% stake in the target company, subject to adjustments for net debt, normalized working capital, and achievement of certain conditions. The acquisition is expected to be completed by January 31, 2026.

    Ace Cardiopathy is engaged in the business of wholesale distribution of medical devices and other healthcare and allied products. The paid-up equity share capital of Ace Cardiopathy is ₹29.81 Lakhs.

    Details of Acquisition

     

    ParticularsDetails
    Name of the target entityM/s. Ace Cardiopathy Solutions Private Limited
    IndustryWholesale distribution of medical devices and other healthcare and allied products
    Cost of acquisition₹59.30 Crore to ₹77.10 Crore
    Percentage of shareholding acquired60%
    Completion DateJanuary 31, 2026
    ConsiderationCash

     

    Ace Cardiopathy Financials

    The revenue details of Ace Cardiopathy are as follows:

     

    (Figures in ₹ Mn.)
    Name of the CompanyF.Y - 2024-2025 (Unaudited)F.Y - 2023-2024 (Audited)F.Y - 2022-2023 (Audited)
    Ace Cardiopathy154817621530

     

    In a separate announcement, Entero Healthcare also informed about the sale of its entire stake (100%) in Suprabhat Pharmaceutical Private Limited, a wholly-owned subsidiary of the Company.

    The details of Income and Networth of Suprabhat Pharmaceutical Private Limited are as follows:

     

    ParticularsAmount (INR in millions)Percentage (%)
    Income198.760.39
    Networth2.380.01

     

    Note: As per the audited financial statements as on March 31, 2025. Percentage reflects Suprabhat's contribution to Entero's Consolidated Income/net worth

    The buyers do not belong to the promoter, promoter group of the Company. However, they were erstwhile promoters of Suprabhat.

    The transaction would be considered as Related Party Transaction and shall be on an Arm's Length basis.

    The Board Meeting commenced at 11:30 AM (IST) and concluded at 01:20 PM (IST).

     

    Alpha Desk
    first published: Sep 29, 2025 01:33 pm

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Subscribe to Tech Newsletters

    • On Saturdays

      Find the best of Al News in one place, specially curated for you every weekend.

    • Daily-Weekdays

      Stay on top of the latest tech trends and biggest startup news.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347